Skip to main content
Premium Trial:

Request an Annual Quote

This Week in Clinical Cancer Research: Mar 16, 2012


In Clinical Cancer Research this week, researchers in Austria and Hungary report their genome-wide microRNA expression profiling of non-small-cell lung cancer. The team analyzed the expression of 856 miRNAs in non-small-cell lung cancer A549 cells both before and after treatment with a DNA methyltransferase inhibitor alone and in combination with a histone deacetylase inhibitor. "By comparing microarray data of untreated and drug-treated A549 cells, we identified 33 miRNAs whose expression was upregulated after drug treatment and which are associated with a CpG island," the authors write. "Thirty of these miRNAs were found to be methylated in at least 1 of 11 NSCLC cell lines analyzed. Moreover, miR-9-3 and miR-193a were found to be tumor specifically methylated in patients with NSCLC." This suggests that methylation is an important mechanism in the inactivation of certain miRNAs in lung cancer, they add.

Also in Clinical Cancer Research this week, researchers in New York and Massachusetts describe a new family of sensitizing EGFR mutations in lung adenocarcinoma. The team studied lung cancer patients with EGFR exon 19 insertions, and found that patients with these insertions were predominately female and never-smokers. "EGFR exon 19 insertions are a newly appreciated family of EGFR-TKI–sensitizing mutations, and patients with tumors harboring these mutations should be treated with EGFR-TKI," the authors write. "While these mutations may be missed through the use of some mutation-specific assays, the addition of PCR product size analysis to multigene assays allows sensitive detection of both exon 19 insertion and deletion mutations."

Finally in Clinical Cancer Research this week, researchers in the US and UK explore combined MEK and VEGFR inhibition in an orthotopic model of human lung cancer. The team injected NCI-H441 or NCI-H460 KRAS-mutant human non-small-cell lung cancer cells into mice, and then treated them with selumetinib, cediranib, paclitaxel, or selumetinib plus cediranib. When control mice began dying, the team assessed the mice in the other groups, and found that selumetinib and cediranib inhibited lung tumor growth and reduced locoregional metastasis. In addition, the team found that the two drugs in combination "markedly enhanced their antitumor effects, with near complete suppression of metastasis." This, the team adds, suggests that "combining selumetinib and cediranib represents a promising strategy for the treatment of NSCLC."

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.